- Home
- ODD vs CTMX Comparison
ODD vs CTMX Comparison
Compare ODD & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | CTMX |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.2M | 716.9M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ODD | CTMX |
|---|---|---|
| Price | $18.91 | $2.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $15.31 | $12.25 |
| AVG Volume (30 Days) | 1.5M | ★ 3.6M |
| Earning Date | 11-18-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.12 | $1.24 |
| P/E Ratio | ★ $16.73 | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.25 | $2.60 |
| 52 Week High | $60.86 | $8.21 |
Technical Indicators
Market Signals| Indicator | ODD | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 37.27 |
| Support Level | $11.71 | N/A |
| Resistance Level | $19.87 | $3.93 |
| Average True Range (ATR) | 1.03 | 0.18 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 72.69 | 17.11 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.